RT Journal Article
SR Electronic
T1 Prevalence of Asymptomatic non-Falciparum and Falciparum Malaria in the 2014-15 Rwanda Demographic Health Survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.09.24301054
DO 10.1101/2024.01.09.24301054
A1 Gaither, Claudia
A1 Morgan, Camille
A1 Kirby, Rebecca
A1 Karema, Corine
A1 Gashema, Pierre
A1 White, Samuel J.
A1 Topazian, Hillary M.
A1 Geibrecht, David
A1 Thwai, Kyaw
A1 Wernsman Young, Neeva
A1 Boyter, Koby
A1 Munyaneza, Tharcisse
A1 Mambo Muvunyi, Claude
A1 De Dieu Butera, Jean
A1 Bailey, Jeffrey A.
A1 Mazarati, Jean-Baptiste
A1 Juliano, Jonathan J.
YR 2024
UL http://medrxiv.org/content/early/2024/12/12/2024.01.09.24301054.abstract
AB Summary Non-falciparum and asymptomatic Plasmodium falciparum malaria are prevalent across Rwanda, with P. falciparum linked to poverty, rural areas, and low elevation. Mixed infections are frequent. Molecular surveillance is crucial to guide effective malaria control efforts.Background Recent molecular surveillance suggests an unexpectedly high prevalence of non-falciparum malaria in Africa. Malaria control is also challenged by undetected asymptomatic P. falciparum malaria resulting in an undetectable reservoir for potential transmission. Context-specific surveillance of asymptomatic P. falciparum and non-falciparum species is needed to properly inform malaria control programs.Methods We performed quantitative real time PCR for four malaria species in 4,595 primarily adult individuals in Rwanda using the 2014-2015 Demographic Health Survey. We assessed correlates of infection by species to explore attributes associated with each species. Asymptomatic P. ovale spp., P. malariae, and P. falciparum malaria infection had broad spatial distribution across Rwanda. P. vivax infection was rare.Results Overall infection prevalence was 23.6% (95%CI [21.7%, 26.0%]), with P. falciparum and non-falciparum at 17.6% [15.9%, 19.0%] and 8.3% [7.0%, 10.0%], respectively. Parasitemias tended to be low and mixed species infections were common, especially where malaria transmission and overall prevalence was the highest. P. falciparum infection was associated with lower wealth, rural residence and low elevation. Fewer factors were associated with non-falciparum malaria.Conclusions Asymptomatic non-falciparum malaria and P. falciparum malaria are common and widely distributed across Rwanda in adults. Continued molecular monitoring of Plasmodium spp. is needed to strengthen malaria control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the National Institutes for Health (R01AI156267 to JAB, JBM and JJJ and K24AI134990 to JJJ). The funding for the DHS was provided by the government of Rwanda, the United States Agency for International Development (USAID), the One United Nations (One UN), the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), World Vison International, the Swiss Agency for Development and Cooperation (SDC), and the Partners in Health (PIH). ICF International provided technical assistance through The DHS Program, a USAID-funded project providing support and technical assistance in the implementation of population and health surveys in countries worldwide. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Dried Blood Spots (DBS) were provided by the Ministry of Health- Rwanda. Clinical and offset GPS data was downloaded from DHS-MEASURE. The University of North Carolina and Brown University IRBs deemed this non-human subjects research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes